106789-32-6

Basic information

• Product Name: L-Proline, 1-[(4-methoxyphenyl)acetyl]-, methyl ester
• CAS NO: 106789-32-6
• Molecular Formula: C15H19NO4
• Molecular Weight: 277.32
• Mol File: 106789-32-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: L-Proline, 1-[(4-methoxyphenyl)acetyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Proline, 1-[(4-methoxyphenyl)acetyl]-, methyl ester(106789-32-6)
• EPA Substance Registry System: L-Proline, 1-[(4-methoxyphenyl)acetyl]-, methyl ester(106789-32-6)

Safety Data

• Hazardous Substances Data: 106789-32-6(Hazardous Substances Data)

Upstream product

• 104-01-8 4-Methoxyphenylacetic acid 
• 2577-48-2 methyl (2S)-pyrrolidine carboxylate 

Downstream Products

• 266001-66-5 TH-1211 
• 133714-80-4 (S)-2-hydroxymethyl-1-(4-methoxyphenethyl)pyrrolidine 

Relevant articles and documents

Chemical inhibitors of the calcium entry channel TRPV6

Purpose: Calcium entry channels in the plasma membrane are thought to play a major role in maintaining cellular Ca2+ levels, crucial for growth and survival of normal and cancer cells. The calcium-selective channel TRPV6 is expressed in prostate, breast, and other cancer cells. Its expression coincides with cancer progression, suggesting that it drives cancer cell growth. However, no specific inhibitors for TRPV6 have been identified thus far. Methods: To develop specific TRPV6 inhibitors, we synthesized molecules based on the lead compound TH-1177, reported to inhibit calcium entry channels in prostate cancer cells in vitro and in vivo. Results: We found that one of our compounds (#03) selectively inhibited TRPV6 over five times better than TRPV5, whereas TH-1177 and the other synthesized compounds preferentially inhibited TRPV5. The IC 50 value for growth inhibition by blocking endogenous Ca2+ entry channels in the LNCaP human prostate cancer cell line was 0.44 ± 0.07 μM compared to TH-1177 (50 ± 0.4 μM). Conclusions:These results suggest that compound #03 is a relatively selective and potent inhibitor for TRPV6 and that it is an interesting lead compound for the treatment of prostate cancer and other cancers of epithelial origin.

Design, synthesis, and biological evaluation of novel T-Type calcium channel antagonists

This paper describes the synthesis of several novel T-type calcium channel antagonists that inhibit calcium influx into the cell, which in turn regulates unknown aspects of the cell cycle pathway that are responsible for cellular proliferation. A library of compounds was synthesized anda brief structure activity relationship will be described. From these studies we have identified a compound (1) that displays anti-proliferative activity in the low micromolar range across a variety of cancer cell lines.